Azenta, Inc. (AZTA)

From the record

Azenta, Inc.'s filings since 2017 show 3 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2025-12-02) (its current reports).

From the record

Azenta, Inc.'s 9 filed years say what it did: revenue went from $527 million in fiscal 2017 to $594 million in fiscal 2025, up 1.5% a year; it rose in 6 of 8 years; the deepest fall was 47% from fiscal 2018 to fiscal 2019; net income was positive in 6 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-09-30, Azenta, Inc.'s diluted share count shrank about 15.1% a year, and dividends and buybacks returned about 100% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 2 purchases of their own stock on the open market in the year to 2026-10-23, buying about $172 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-09-30, Azenta, Inc. lost about 3 cents for every dollar of shareholders' money, and gross profitability: its products earned about 13 cents per dollar of everything the company owns. Leverage: it owed about 16 cents per dollar of assets, and net share issuance: its share count shrank 13.7% over the year (the filed statements).

From the record

Azenta, Inc.'s standing among 13 graded names in its industry family: revenue of $594 million in fiscal 2025 ranks in the top 46% by size; a net margin of -9.4% ranks in the bottom 19%; revenue growth of 2.2% a year over the last 3 filed years ranks in the top 50% (its annual reports).

From the record

Azenta, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Madaus, Martin D (Interim CEO, as filed), filing under that title since 2026-09-16, 2 months (bottom 13% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 2.1 years (bottom 13%); 13 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (bottom 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Azenta, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $280 million against no long-term debt tagged leaves 13.6% of its assets as net cash, bottom 35% of its family; cash from operations less capital spending is 6.5% of revenue (bottom 35%); a gross margin of 45.5% (top 42%); research spending of 5.1% of revenue (bottom 13%) (its annual report).

From the record

Azenta, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.2% a year over the last three filed years against 1.5% over all 9, speeding up (top 19% of its family); the newest year grew 3.6% (top 42%); research spending grew 3.3% a year (bottom 35%); capital spending grew -22.7% a year (bottom 46%) (its annual reports). Azenta, Inc. reported 3 lines of business in fiscal 2025: Multiomics at $269 million (45%), Core Products at $198 million (33%), Sample Repository Solutions at $127 million (21%); 3 of 3 grew against the year before (its annual report).

From the record

Azenta, Inc.'s newest year against its own record: revenue of $594 million in fiscal 2025 came in 1.9% above the $583 million its prior three years' pace pointed to (top 35% of its family); net income of $56 million against a prior three-year average of $651 million (bottom 12%); a net margin of -9.4% against more than its whole revenue before (bottom 4%) (its annual reports).